As U.S. FDA Chief Hamburg Commences India Visit, Government Bats For Generic Industry
This article was originally published in PharmAsia News
Executive Summary
Against a backdrop of increased regulatory scrutiny of Indian drug makers, FDA Commissioner Margaret Hamburg met with India’s health and commerce ministers, who expressed concern over the agency’s “disproportionate penalties” on Indian generics firms.